Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experienceE.S. Lutrino, Saverio Cinieri, Marianna Giampaglia et al.|Tumori Journal|2019Cited by 6
A multicenter phase II trial of nab‐paclitaxel and capecitabine in HER‐2 negative and triple‐ negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?Mariangela Ciccarese, Laura Orlando, Palma Fedele et al.|The Breast Journal|2020Cited by 0